Kennedy Opens Access to Six Unapproved Peptides Despite FDA Opposition

The push centers on unapproved peptide injections promoted for wellness, including by online influencers. Health Secretary Robert F. Kennedy Jr. favored wider access, but the FDA had advised against the move, according to The New York Times.

The opposition extended through the agency's scientific staff. Most FDA scientists opposed the plan and had limited input into its drafting, Fast Company reported. The dispute was not simply about availability, but about expanding access to drugs whose benefits and risks remain unproven.

On October 28, the Department of Health and Human Services released a policy temporarily allowing compounding pharmacies to manufacture some peptide products, STAT News reported. The change covers six peptides, according to NBC News.

The immediate mechanism is a promise not to take enforcement action against licensed pharmacists who dispense certain unapproved peptides, TIME.com reported. That opens a route to consumers without the products first receiving standard FDA approval.

The permission also extends to compounded combinations of the six peptides dispensed by certain pharmacies, according to Scientific American Content: Global Science. The policy therefore reaches beyond access to individual peptide products.

HHS explicitly limited what the decision means medically. "The policy does not ... establish clinical safety and effectiveness," the department said, according to ABCNews.com.

By October 29, coverage continued to describe the change as an expansion of access despite the FDA's advice against using the injections, as The Independent reported. No completed formal rule change is described in the supplied coverage.

The immediate position is temporary permission, not FDA approval. Compounding pharmacies have a green light to make the six peptides while HHS continues work on a formal rule change, according to NBC News.

Availability is also separate from evidence. There is little evidence that the wellness peptides are safe and effective, CBS Top Stories reported. HHS's own disclaimer leaves that central uncertainty unresolved.

The next regulatory step is the formal rule change still being developed, according to NBC News. Its outcome will matter because the current permission is temporary.

A separate question is how much access will actually expand. Small compounding pharmacies may not be able to meet demand, NPR News reported. Permission to manufacture does not by itself establish how widely the products will become available.